Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Candidiasis update

    Project Inform Perspective
    |May 30, 2003
    PubMed
    Summary
    This summary is machine-generated.

    Potent anti-HIV therapy boosts immune cells, allowing some opportunistic infection treatments to stop. However, candidiasis rates remain unchanged despite these advances in HIV management.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010
    See all related articles

    Area of Science:

    • Immunology
    • Infectious Diseases
    • HIV/AIDS Research

    Background:

    • Potent antiretroviral therapy (ART) significantly increases CD4+ T-cell counts in individuals with HIV.
    • This immune recovery has led to revised guidelines, enabling the discontinuation of certain prophylactic and maintenance therapies for opportunistic infections (OIs).
    • The cessation of OI therapies is considered safe when immune response is robust, reducing treatment burden and potential side effects.

    Discussion:

    • While ART has dramatically reduced the incidence of many HIV-related opportunistic infections, a notable exception is candidiasis.
    • The fungal infection candidiasis has not shown a similar decline in prevalence or incidence despite improvements in immune status.
    • This suggests that candidiasis may require different management strategies or that factors beyond CD4+ counts influence its occurrence in treated HIV patients.

    Related Experiment Videos

    Key Insights:

    • Sustained increases in CD4+ cell counts due to effective HIV treatment correlate with decreased rates of many opportunistic infections.
    • The success in managing OIs highlights the efficacy of modern antiretroviral therapy in restoring immune function.
    • Candidiasis represents a persistent challenge, as its incidence has not been significantly impacted by the same therapeutic advances that benefit other OIs.

    Outlook:

    • Further research is needed to understand the specific mechanisms underlying persistent candidiasis in HIV-positive individuals with improved immune status.
    • Investigating alternative or adjunctive therapies for candidiasis may be necessary.
    • Long-term monitoring and analysis of OI incidence in the context of evolving HIV treatment protocols are crucial for refining clinical practice.